Perspective Therapeutics reports Q1 2026 net loss of $26.2M; cash raised to $271M

Perspective Therapeutics, Inc.

• Net loss $26.2M ($0.25/share) vs. $18.2M net loss in Q1 2025; R&D spend up 50% YoY to $21.4M.
• Cash, equivalents & short-term investments $271M as of Mar 31, 2026, up from $145M at Dec 31, 2025; includes $164M net from Feb 2026 offering.
• Cash runway expected into late 2027 to support clinical milestones; lead program VMT-α-NET advancing to Cohort 4 and meningioma cohort.
• VMT01 (melanoma) dosing cohorts closed after 10 patients treated at 3.0 mCi; PSV359 (FAP) Cohort 3 open.
• Chicago manufacturing site on track to complete construction in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.